136 related articles for article (PubMed ID: 37767551)
21. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.
Lussana F; Carobbio A; Salmoiraghi S; Guglielmelli P; Vannucchi AM; Bottazzi B; Leone R; Mantovani A; Barbui T; Rambaldi A
J Hematol Oncol; 2017 Feb; 10(1):54. PubMed ID: 28228104
[TBL] [Abstract][Full Text] [Related]
22. Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice.
Chen Y; Shan Y; Lu M; DeSouza N; Guo Z; Hoffman R; Liang A; Li S
Cancer Res; 2017 Jan; 77(1):164-174. PubMed ID: 27784744
[TBL] [Abstract][Full Text] [Related]
23. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events.
Alvarez-Larrán A; Bellosillo B; Pereira A; Kerguelen A; Hernández-Boluda JC; Martínez-Avilés L; Fernández-Rodríguez C; Gómez M; Lombardía L; Angona A; Ancochea A; Senín A; Longarón R; Navarro B; Collado M; Besses C
Am J Hematol; 2014 May; 89(5):517-23. PubMed ID: 24458835
[TBL] [Abstract][Full Text] [Related]
24. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
Wernig G; Mercher T; Okabe R; Levine RL; Lee BH; Gilliland DG
Blood; 2006 Jun; 107(11):4274-81. PubMed ID: 16478879
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of vorinostat in a murine model of polycythemia vera.
Akada H; Akada S; Gajra A; Bair A; Graziano S; Hutchison RE; Mohi G
Blood; 2012 Apr; 119(16):3779-89. PubMed ID: 22408262
[TBL] [Abstract][Full Text] [Related]
26. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations.
Okabe M; Yamaguchi H; Usuki K; Kobayashi Y; Kawata E; Kuroda J; Kimura S; Tajika K; Gomi S; Arima N; Mori S; Ito S; Koizumi M; Ito Y; Wakita S; Arai K; Kitano T; Kosaka F; Dan K; Inokuchi K
Leuk Res; 2016 Jan; 40():68-76. PubMed ID: 26614694
[TBL] [Abstract][Full Text] [Related]
27. Distinguishing essential thrombocythemia
Silver RT; Krichevsky S
Haematologica; 2019 Nov; 104(11):2200-2205. PubMed ID: 30948488
[TBL] [Abstract][Full Text] [Related]
28. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?
Verstovsek S; Silver RT; Cross NC; Tefferi A
Leukemia; 2006 Nov; 20(11):2067. PubMed ID: 16990780
[No Abstract] [Full Text] [Related]
29. Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.
Mansier O; Kilani B; Guitart AV; Guy A; Gourdou-Latyszenok V; Marty C; Parrens M; Plo I; Vainchenker W; James C
Blood; 2019 Dec; 134(26):2383-2387. PubMed ID: 31697834
[TBL] [Abstract][Full Text] [Related]
30. Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme.
Roda P; Ferrari A; Tang X; Erlich P; Eisenhower C; Patel MD; Irvin-Barnwell EA
Ann Hematol; 2014 Sep; 93(9):1467-72. PubMed ID: 24687383
[TBL] [Abstract][Full Text] [Related]
31. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.
Verger E; Soret-Dulphy J; Maslah N; Roy L; Rey J; Ghrieb Z; Kralovics R; Gisslinger H; Grohmann-Izay B; Klade C; Chomienne C; Giraudier S; Cassinat B; Kiladjian JJ
Blood Cancer J; 2018 Oct; 8(10):94. PubMed ID: 30287855
[TBL] [Abstract][Full Text] [Related]
32. Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications.
Soriano G; Heaney M
Curr Opin Hematol; 2013 Mar; 20(2):169-75. PubMed ID: 23298878
[TBL] [Abstract][Full Text] [Related]
33. JAK2 exon 12 mutation in JAK2V617F-negative polycythemia vera.
Röthlisberger B; Huber A; Bargetzi M; Mendez A; Heizmann M
Leuk Lymphoma; 2008 Mar; 49(3):586-8. PubMed ID: 18297539
[No Abstract] [Full Text] [Related]
34. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
35. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
[TBL] [Abstract][Full Text] [Related]
36. Congenital JAK2V617F polycythemia vera: where does the genotype-phenotype diversity end?
Kelly K; McMahon C; Langabeer S; Eliwan H; O'Marcaigh A; Smith OP
Blood; 2008 Nov; 112(10):4356-7. PubMed ID: 18988882
[No Abstract] [Full Text] [Related]
37. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.
Godfrey AL; Chen E; Pagano F; Ortmann CA; Silber Y; Bellosillo B; Guglielmelli P; Harrison CN; Reilly JT; Stegelmann F; Bijou F; Lippert E; McMullin MF; Boiron JM; Döhner K; Vannucchi AM; Besses C; Campbell PJ; Green AR
Blood; 2012 Sep; 120(13):2704-7. PubMed ID: 22898600
[TBL] [Abstract][Full Text] [Related]
38. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
[TBL] [Abstract][Full Text] [Related]
39. Nongenetic stochastic expansion of JAK2V617F-homozygous subclones in polycythemia vera?
Godfrey AL; Nangalia J; Baxter EJ; Massie CE; Kent DG; Papaemmanuil E; Campbell PJ; Green AR
Blood; 2014 Nov; 124(22):3332-4. PubMed ID: 25414437
[No Abstract] [Full Text] [Related]
40. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
Sirhan S; Lasho TL; Hanson CA; Mesa RA; Pardanani A; Tefferi A
Am J Hematol; 2008 May; 83(5):363-5. PubMed ID: 18266209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
